Welcome to our dedicated page for BioCardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. filed a current report describing a communication about one of its clinical programs. The company furnished a press release announcing primary endpoint results from the open label roll-in cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The press release is included as Exhibit 99.1 and is treated as furnished, not filed, under securities law.
BioCardia, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original registration statement unchanged and focuses on updating and organizing the exhibit list, including agreements related to prior mergers, equity incentive plans, various securities purchase and warrant agreements, indemnification and change of control arrangements for executives, leasing arrangements, and at-the-market and other offering agreements with financial firms. The filing also includes legal opinions, auditor consents, and technical XBRL documents, and is signed by the President and Chief Executive Officer and the Chief Financial Officer, along with the company’s directors under a power of attorney.
BioCardia, Inc. is registering up to 2,800,000 shares of common stock, up to 2,800,000 pre-funded warrants, up to 2,800,000 common warrants, and the shares of common stock issuable upon exercise of those warrants in a best efforts public offering. Each share or pre-funded warrant will be sold together with one common warrant, at an assumed combined public offering price of $2.27. The company expects net proceeds of about $5.3 million if all securities are sold, and estimates that, with current quarterly cash use of roughly $1.6 million, this funding would support operations into the second quarter of 2026.
BioCardia is a clinical-stage developer of bone marrow–derived cell and cell‑derived therapies for heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. The company is currently not in compliance with Nasdaq’s $2.5 million minimum stockholders’ equity rule and has been granted until September 29, 2025 to regain compliance. The offering is highly dilutive, carries no minimum raise or escrow, and involves speculative short‑dated warrants whose value depends on future stock price and stockholder approval in certain cases.